CN112915137A - Agilawood preparation and preparation method and application thereof - Google Patents

Agilawood preparation and preparation method and application thereof Download PDF

Info

Publication number
CN112915137A
CN112915137A CN202110157791.9A CN202110157791A CN112915137A CN 112915137 A CN112915137 A CN 112915137A CN 202110157791 A CN202110157791 A CN 202110157791A CN 112915137 A CN112915137 A CN 112915137A
Authority
CN
China
Prior art keywords
agilawood
parts
preparation
solubilizer
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110157791.9A
Other languages
Chinese (zh)
Inventor
孙勇伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Ruixiangzhuang Trading Co ltd
Original Assignee
Beijing Ruixiangzhuang Trading Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Ruixiangzhuang Trading Co ltd filed Critical Beijing Ruixiangzhuang Trading Co ltd
Priority to CN202110157791.9A priority Critical patent/CN112915137A/en
Publication of CN112915137A publication Critical patent/CN112915137A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
    • A61K36/835—Aquilaria
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/01—Deodorant compositions
    • A61L9/012—Deodorant compositions characterised by being in a special form, e.g. gels, emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/01—Deodorant compositions
    • A61L9/013—Deodorant compositions containing animal or plant extracts, or vegetable material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Abstract

The invention belongs to the technical field of agilawood preparations, and discloses an agilawood preparation as well as a preparation method and an application thereof. The preparation adopts the agilawood extract as a main raw material component, and the solubilizer, the cosolvent and the qi regulating agent are added in a reasonable compatibility mode, so that the precipitation and the more sufficient mutual fusion of effective components in the agilawood are further promoted, and the qi regulating agent can promote the smooth breathing of a user. The sweetening agent and the flavoring agent add faint scent to the preparation. The preparation method of the agilawood preparation has simple flow, wide and rich use sources of raw materials, and the prepared product has safety and stability, has no toxic or side effect, and is suitable for mass production. The final product can be widely applied in spray, aroma pill, and incense product.

Description

Agilawood preparation and preparation method and application thereof
Technical Field
The invention belongs to the technical field of agilawood preparations, and particularly relates to an agilawood preparation as well as a preparation method and an application thereof.
Background
Aquilaria sinensis, a wood containing resin, is Gilg (Lour.) or Aquilaria agallocha Roxb. China has aquilaria sinensis and Yunnan agilawood, the aquilaria sinensis is distributed in Yunnan, Guangdong, Guangxi and Hainan, and the Yunnan agilawood is only distributed in Yunnan. The agilawood is a pathological tissue remained after the aquilaria sinensis tree trunk is influenced by external adverse factors, is generally brown to dark black, and has improved quality along with deepening of color. The eaglewood tree is a treasure on the whole body, and flowers, fruit peels and leaves can be used as tea and medicines.
According to the relevant research data, the relevant parts of the lignum aquilariae resinatum, such as leaves and agilawood leaves, contain volatile oil, flavone and glycosides thereof, phenols, triterpenes, polysaccharides and amino acids, and the chemical components have various physiological activities of resisting inflammation, easing pain and the like.
With the improvement of living standard and the enhancement of health care consciousness of people, safe and healthy health products are more and more concerned. Along with the research and the recognition of the agilawood in recent years, not only the final agilawood product is recognized and chastetree in the market, but also products processed by agilawood leaves, agilawood branches, agilawood flowers and agilawood fruits are developed and recognized. Has the effects of promoting qi circulation, relieving pain, warming middle-jiao, arresting vomiting and relieving asthma, and can be used for treating chest and abdomen distention, pain, stomach cold, emesis, vomiting, kidney deficiency, adverse rising of qi, and asthma.
At present, the agilawood is mostly used for soaking medicinal liquor, or extracting essential oil, or making substances such as agilawood paste by using agilawood sawdust, branches and stems thereof and the like, and the above mode not only needs to consume a large amount of agilawood raw materials in the making process, but also consumes time and labor. And at present, the product preparation and the like using the agilawood for tranquilizing, sterilizing and other effects are complex in process and low in sterilization rate.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide an agilawood preparation and a preparation method and application thereof.
The technical scheme adopted by the invention is as follows: the agilawood preparation is mainly prepared from the following raw materials in parts by mass:
20-150 parts of agilawood extract, 8-60 parts of solubilizer, 5-50 parts of cosolvent, 2-5 parts of air regulator, 2-7 parts of sweetener and 2-7 parts of aromatizer.
The invention provides an agilawood preparation, which is prepared by selecting an agilawood extract as a main raw material component and adding a solubilizer, a cosolvent and a gas regulator in a reasonable compatibility mode, so that the precipitation and the more sufficient mutual fusion of effective components in agilawood are further promoted, and the gas regulator can promote the smooth breathing of a user. The sweetening agent and the flavoring agent add faint scent to the preparation.
Preferably, the preparation is mainly prepared from the following raw materials in parts by mass:
50-120 parts of agilawood extract, 20-48 parts of solubilizer, 10-38 parts of cosolvent, 2.5-4.5 parts of air regulator, 3-5 parts of sweetener and 3-5 parts of aromatizer.
Preferably, the preparation is mainly prepared from the following raw materials in parts by mass:
80 parts of agilawood extract, 32 parts of solubilizer, 30 parts of cosolvent, 3.5 parts of air regulator, 4 parts of sweetener and 4 parts of excipient.
Preferably, the solubilizer comprises hydrogenated castor oil;
the hydrogenated castor oil comprises one or more of PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil and PEG-80 hydrogenated castor oil;
the co-solvent comprises glycerol.
Preferably, the gas regulating agent comprises menthone glycerol ketal;
the sweetener comprises trichlorogalactose.
Preferably, the odorant comprises one or more of menthol and bromelain.
PEG-60 hydrogenated castor oil is a commonly used high-efficiency solubilizer, and can uniformly disperse oily substances such as essence, essential oil and the like into water to form a stable and transparent solution. The starting material is from a natural plant, namely hydrogenated castor oil, can be biodegraded in nature, and is suitable for industries of pesticides, coatings, daily chemicals, water-based ink, textile, printing and dyeing, papermaking, cosmetics and the like. Is a modified castor oil product which is easy to decompose and has no residue.
Glycerol and glycerol are colorless, sweet, clear, viscous liquids. No bad smell. Has warm and sweet taste. Commonly known as glycerin, absorbs moisture from the air, and also absorbs hydrogen sulfide, hydrogen cyanide and sulfur dioxide. Insoluble in benzene, chloroform, carbon tetrachloride, carbon disulfide, petroleum ether and oils. Relative density 1.26362. Melting point 17.8 ℃. Boiling point 290.0 deg.c (decomposition). Refractive index 1.4746. Flash point (open cup) 176 ℃. Acute toxicity: LD50:31500mg/kg (rat oral). Glycerol is a backbone component of the triglyceride molecule. When the human body takes in the edible fat, triglyceride in the edible fat is metabolized and decomposed in the body to form glycerol and is stored in fat cells. Thus, the end products of triglyceride metabolism are glycerol and fatty acids. Can be used as solvent, lubricant, medicament and sweetener.
Menthone glycerol ketal, a colorless, transparent, viscous liquid, dissolved in water. It can be used in oral cavity care product to enhance mint flavor, or in chewing gum, syrup, and spice flavoring agent to mask bitter taste. The aroma characteristics are as follows: 10% concentration, almost no aroma. Taste characteristics: the concentration of 5-10 mg/kg can make the mouth feel gradually enhanced cool and the throat feel quickly, and the throat feels slightly irritated and burned with cool taste. The cool taste is continuously strengthened and is not easy to feel for a long time.
Trichlorogalactose is used as one of food sweetener, nutritional supplement and essential amino acid. Sucralose is a new approved sweetener in China. The Chinese regulation can be used for pickles, compound seasonings, compound wine, beverages, ice cream, frozen sucker, cakes, canned fruits, biscuits and bread, and the maximum use amount is 2.5 g/kg; the maximum use amount of the chewing gum in the preserved fruit and the modified chewing gum is 1.5 g/kg; can also be used as table sweetener, with maximum dosage of 0.05 g/bag or tablet. No nutritive sweetener. The synthesized sweetener activates a T1R2/T1R3 sweet taste receptor on enteroendocrine cells (enteroendocrine cells), and induces the secretion of hyperglycemic factor polypeptide and insulinotropic polypeptide hormone.
Menthol, a chemical agent, is extracted from the leaves and stems of Mentha arvensis, white crystals, formula C10H20OIs the main component of peppermint and peppermint essential oils. India is the major natural mint producing country in the world. Menthol and racemic menthol can be used as toothpaste; a perfume; flavoring agent for beverage and candy. It can be used as irritant in medicine, and has effects in refreshing and relieving itching; can be taken orally as a wind-expelling medicine for treating headache and nose; pharynx; laryngitis and the like. The esters thereof are useful in perfumery and in pharmaceuticals. It can be used as irritant in medicine, and has effects in refreshing and relieving itching; it can be used as wind-expelling medicine for treating headache, and inflammation of nose, pharynx, and larynx.
Pineapple ester with molecular formula C12H20O2Widely used in food industry and also used as an odorant.
A preparation method of lignum Aquilariae Resinatum preparation comprises selecting lignum Aquilariae Resinatum extract, solubilizer, cosolvent, air regulating agent, sweetener and flavoring agent according to corresponding proportion, mixing, adding antiseptic and solvent, mixing, filtering, and sterilizing to obtain the final product.
The preparation method of the agilawood preparation has simple flow, wide and rich use sources of the raw materials, and the prepared product has safety and stability, has no toxic or side effect, and is suitable for mass production.
Preferably, the preservatives include lysozyme and sodium benzoate;
the mass ratio of the lysozyme to the sodium benzoate is 1-3: 1-2;
the solvent water;
the mass ratio of the total mass of the agilawood extract, the solubilizer, the cosolvent, the air regulator, the sweetening agent and the flavoring agent to the mass of the preservative to the mass of the solvent is 10-20: 2-4: 3-5.
Lysozyme (also called muramidase) or N-acetylmuramidase hydrolase (N-acetylmuramidase glycohydrolase) is an alkaline enzyme that hydrolyzes mucopolysaccharides in pathogenic bacteria. The bacterial lysis is achieved by breaking the beta-1, 4 glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine in the cell wall, breaking down the cell wall insoluble mucopolysaccharide into soluble glycopeptides, causing the contents of the broken cell wall to escape. Lysozyme can also be directly combined with virus protein with negative charge, and forms double salt with DNA, RNA and apoprotein to inactivate virus. Therefore, the enzyme has the functions of antibiosis, antiphlogosis, antivirus, etc.
Sodium benzoate (chemical formula: C)6H5CO2Na), E number E211, is the sodium salt of benzoic acid. Sodium benzoate is an acidic preservative which has better preservative effect in an acidic environment, is a very common food preservative, has the effects of preventing deterioration and acidification and prolonging the shelf life, and is widely used in various countries in the world. However, in recent years, the toxicity of the sodium benzoate has been considered to be a concern, so that the use of the sodium benzoate has been limited, and some countries such as Japan have stopped producing sodium benzoate and have made restrictions on the use thereof. Most of the sodium benzoate is white particles, has no odor or slight benzoin smell, has slightly sweet taste and astringency; is easy to dissolve in water (normal temperature) about 53.0g/100ml, and has a PH of about 8; sodium benzoate is also an acidic preservative, and has no sterilization and bacteriostasis effects in an alkaline medium; the optimal pH for preservation is 2.5-4.0, and 5% solutions at pH5.0 also have poor bactericidal effects. The sodium benzoate has larger lipophilicity, is easy to penetrate cell membranes to enter cell bodies, interferes the permeability of the cell membranes, and inhibits the absorption of the cell membranes to amino acid; enter into the cell body to ionize and acidify the alkali storage in the cell and inhibit the activity of the respiratory enzyme system of the cell,prevent the condensation reaction of acetyl coenzyme A, thereby achieving the purpose of food preservation.
Preferably, the sterilization temperature is 80-100 ℃;
the sterilization time is 5-10 minutes.
The application of the finished product of the agilawood preparation in sprays, aromatherapy pills and incense products is disclosed in any one of claims 1 to 3.
The invention has the beneficial effects that:
the invention provides an agilawood preparation, which is prepared by selecting an agilawood extract as a main raw material component and adding a solubilizer, a cosolvent and an air regulating agent in a reasonable compatibility mode, so that the precipitation and the more sufficient mutual fusion of effective components in agilawood are further promoted, and the air regulating agent can promote the smooth breathing of a user. The sweetening agent and the flavoring agent add faint scent to the preparation. The preparation method of the agilawood preparation has simple flow, wide and rich use sources of raw materials, and the prepared product has safety and stability, has no toxic or side effect, and is suitable for mass production. The final product can be widely applied in spray, aroma pill, and incense product.
Detailed Description
The present invention is further illustrated below with reference to specific examples. It will be appreciated by those skilled in the art that the following examples, which are set forth to illustrate the present invention, are intended to be part of the present invention, but not to be construed as limiting the scope of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The examples were carried out under the conventional conditions, unless otherwise specified. The reagents used are all conventional products which are commercially available.
Example 1:
a preparation method of an agilawood preparation comprises the steps of selecting 200 g of agilawood extract, 80 g of PEG-40 hydrogenated castor oil, 50 g of glycerol, 20 g of menthone glycerol ketal, 20 g of trichlorogalactose and 20 g of menthol according to corresponding proportions, uniformly mixing, adding 47 g of lysozyme, 47 g of sodium benzoate and 141 g of water, uniformly mixing, filtering, and sterilizing at 80 ℃ for 5 minutes to obtain a finished product.
Example 2:
a preparation method of an agilawood preparation comprises selecting 1500 g of agilawood extract, 600 g of PEG-60 hydrogenated castor oil, 500 g of glycerol, 50 g of menthone glycerol ketal, 70 g of trichlorogalactose and 70 g of pineapple ester according to corresponding proportion, mixing uniformly, adding 392.4 g of lysozyme, 261.6 g of sodium benzoate and 817.5 g of water, mixing uniformly, filtering, and sterilizing at 100 ℃ for 10 minutes to obtain a finished product.
Example 3:
a process for preparing the eaglewood preparation comprises proportionally mixing the extracts of eaglewood 500 g, PEG-40 hydrogenated castor oil 200 g, glycerin 100 g, menthone glycerin ketal 25 g, trichlorogalactose 30 g and menthol 30 g, adding lysozyme 105.5 g, sodium benzoate 105.5 g and water 316.5 g, mixing, filtering, and sterilizing at 80 deg.C for 5min to obtain the final product.
Example 4:
a preparation method of an agilawood preparation comprises the steps of selecting 1200 g of agilawood extract, 480 g of PEG-60 hydrogenated castor oil, 380 g of glycerol, 45 g of menthone glycerol ketal, 50 g of trichlorogalactose and 50 g of pineapple ester according to corresponding proportions, uniformly mixing, adding 311.4 g of lysozyme, 207.6 g of sodium benzoate and 778.5 g of water, uniformly mixing, filtering, and sterilizing at 100 ℃ for 10 minutes to obtain a finished product.
Example 5:
a process for preparing eaglewood preparation comprises selecting 800 g of eaglewood extract, 320 g of PEG-60 hydrogenated castor oil, 300 g of glycerol, 35 g of menthone glycerol ketal, 40 g of trichlorogalactose and 40 g of menthol according to corresponding proportion, mixing uniformly, adding 181.5 g of lysozyme, 181.5 g of sodium benzoate and 544.5 g of water, mixing uniformly, filtering, sterilizing at 80 ℃ for 10 minutes to obtain the final product.
PEG-60 hydrogenated castor oil, manufacturer: wuhan is far from the co-creation technology company Limited.
Glycerol, manufacturer: wuhan is far from the co-creation technology company Limited.
Menthone glycerol ketal, manufacturer: wuhan is far from the co-creation technology company Limited.
Trichlorogalactose, manufacturer: shanghai Hotan Biotechnology Ltd.
Menthol, manufacturer: jishui county Jianmin Natural spice oil factory.
Lysozyme, manufacturer: shanghai such as Ji Biotech, Inc.
Sodium benzoate, manufacturer: shandong Jinan Kunfeng chemical Co., Ltd.
In the actual operation process of all the embodiments, the selected blending device comprises a three-dimensional motion mixer, stainless steel materials with specification models of SYH-30 and SYH-1000, and manufacturers: jiangyin and Rong mechanical Co. The selection of the stirring device is not limited to the above, and all devices which can complete the corresponding stirring work and have no influence on raw materials belong to the protection scope of the invention.
In the actual operation process of all the above embodiments, the filter pressing device selected for use comprises a filter press, and is made of stainless steel, and the specification and model are as follows: x (AM) G30/870-30U, manufacturer: shanghai Shangding machinery, Inc. The selection of the filter pressing device is not limited to the above, and all devices which can complete the corresponding filter pressing work and have no influence on the whole reaction belong to the protection scope of the invention.
In the actual operation process of all the embodiments, the selected high-temperature sterilization device comprises an ultrahigh-temperature instantaneous sterilizer which is made of stainless steel and has the specification and model number: RP6L10, manufacturer: shanghai Taiwan light tools and equipments Ltd. The selection of the high-temperature sterilization device is not limited to the selection provided above, and all devices which can complete the corresponding high-temperature sterilization work and have no influence on the overall reaction belong to the protection scope of the invention.
In the actual operation process of all the above embodiments, if the finished product is expected to be made into fragrance pills or pastille and the like, the treatment is carried out by utilizing mechanical equipment. The concentrator that chooses for use includes that vacuum concentration evaporates the appearance soon, specification model: TQG, manufacturer: wenzhou worker big light industry machinery, Inc. The selection of the type of the above-mentioned concentrating equipment and the selection of the manufacturer can be set according to the actual environment and actual requirements in the specific implementation process. The invention belongs to the protection scope of the invention, wherein the concentration can be realized without influencing the components of the finished product.
In the practical operation process, the finished product needs to be packaged, and a horizontal packaging machine and an ink-jet printer are respectively selected. The horizontal packaging machine is made of stainless steel, the specification and model are SG-180, and a manufacturer: shanghai plastic packaging science and technology, Inc. The ink jet numbering machine is made of stainless steel, the specification and model are V803-D, and a manufacturer: beijing Oriental Union technologies, Inc.
The first experimental example:
purpose of the experiment: antibacterial experiment of the final product
The experimental method comprises the following steps: the sterilization effect is tested by utilizing a 'determination method of biological activity of the bactericide-bacteriostasis ring method'.
The experimental principle is as follows: the basic principle of the inhibition zone method is that a small amount of antibacterial substance or bactericide is applied to LAB (beef extract peptone agar medium) inoculated with test bacteria to contact with the medium and germs, and after the test bacteria are cultured for a certain time at a fixed temperature, the bacteria are killed around the application part to inhibit the growth of the bacteria on the medium due to the permeation and diffusion of the medicament, so that an inhibition zone is generated. Within a certain range, the square or the area of the diameter of the inhibition zone and the logarithm of the concentration of the medicament form a linear function relationship, so that the magnitude of the bactericidal activity of the test sample can be compared. The bacteriostatic loop method has the advantages of high accuracy, simple operation and capability of rapidly obtaining results.
The experimental method comprises the following steps: the tube-disc method is adopted.
The experimental steps and processes are as follows:
preparing a liquid medicine: 5mL of the product in each example is selected and respectively blended with 100mL of sterilized distilled water to prepare 5 kinds of test agent liquid medicines. 75% alcohol sanitizer was used as a control. 5mL of the control group liquid medicine was extracted, and 100mL of sterilized distilled water was added to dilute the control group liquid medicine to obtain the control group test agent liquid medicine as a control group 1. Sterile distilled water was selected as a blank control group for the above experiment as a control group 2.
② culturing strains: the prepared LAB medium was poured into 35 dishes of identical amount of medium that had been sterilized. 35 dish media were randomly divided into 7 groups and encoded: 1-5, 7 parts of culture medium in each group. Wherein, the first group of culture medium is inoculated with pseudomonas aeruginosa; inoculating staphylococcus aureus in the second group of culture medium; inoculating hemolytic streptococcus in the third group of culture medium; inoculating Escherichia coli in the fourth group of culture medium; candida albicans was inoculated into the fifth group of culture medium and cultured at a constant temperature. (this step completed the culture process before the experiment was performed)
Preparing a suspension of the test bacteria: pouring 10mL of sterile water into the five groups of strains cultured in the second step, lightly scraping the strain plane by using an inoculating needle to suspend the spores, then pouring the spores into a sterilized triangular flask (a plurality of glass beads are filled in advance) and shaking for 5min, and filtering the spore suspension into the other sterilized triangular flask by using a sterilized double-layer gauze. Examining with low-power (15 × 20 times) microscope, adjusting spore concentration, preferably 80-100 spores per visual field, and performing the above operations under sterile condition with rapidity and accuracy. Spore suspensions of five groups of species were made complete according to the procedure described above.
Fourthly, pouring a double-layer culture medium: the prepared LAB was poured into a 9cm diameter petri dish and condensed horizontally. And (3) melting the culture medium suitable for the growth and development of the five groups of test bacteria, cooling to about 45-50 ℃, respectively and quickly sucking 10mL of bacterial liquid of each of the five groups of strains, adding the bacterial liquid into the culture medium, fully and uniformly mixing, immediately sucking 5mL of bacteria-bearing culture medium, adding the culture medium on the solidified LAB, and uniformly spreading the culture medium on the bottom layer. According to the method, each strain is uniformly laid in 7 culture dishes of each group respectively according to the grouping corresponding to the corresponding strain set in the step two.
Fifthly, medicine injection: and clamping a small stainless steel tube by using a pair of sterilized tweezers, wherein the small stainless steel tube is used for placing the reagent to be tested on the surface of the LAB, and is reserved for standby after the culture is finished at a constant temperature in a small cylinder made of stainless steel. Placing 1 stainless steel small tube in each culture dish, wherein 1 small tube is placed for control group 1 to be tested with medicinal liquid, 1 small tube is placed for control group 2, and the other 5 small tubes are 5 kinds of example medicinal liquid (medicinal liquid is added to form a convex surface at the tube mouth) of the lignum Aquilariae Resinatum preparation, and culturing at suitable temperature.
Sixthly, the result is that: after culturing for a certain time, taking out the culture dish, measuring the diameter of the inhibition zone by a cross method, and evaluating the bactericidal activity according to the existence and the size of the inhibition zone.
And (3) detection results:
TABLE 1 bacteriostatic action of test agents on five groups of test bacteria
Figure BDA0002934453460000101
Note: the diameter data obtained in the above table are the average of the diameters of the zones of inhibition present in one dish, which are statistically significant.
The results in table 1 show that, in the examples of the agilawood preparation provided by the invention, examples 4 and 5 have very strong bacteriostatic effects on the five groups of test bacteria. The other examples also have obvious bacteriostatic effects on the five groups of test bacteria. From the data in the table, it can be found that the diameters of the inhibition zones of the five groups of test bacteria show a trend of increasing with the increasing concentration of each example.
The diameters of the inhibition zones generated by the control group 1 diluted liquid medicine on the above 5 bacteria show that the control group 1 diluted liquid medicine has obvious inhibition effects on staphylococcus aureus, escherichia coli and candida albicans, and has the same effect on inhibiting pseudomonas aeruginosa but has a slightly weak effect.
In conclusion, the agilawood preparation provided by the invention can obviously inhibit pseudomonas aeruginosa, staphylococcus aureus, hemolytic streptococcus, escherichia coli and candida albicans.
Experiment example two: oral toxicity test in mice
Experimental drugs: examples 1-5 the finished spray was prepared.
Experimental animals: 50 mice of Kunming species are selected, and the male and female are half of each other. They were randomly divided into 5 groups of half male and female each, and gavage was given at a dose of 2mL per group. LD thereof50More than 10000mg/Kg, and is classified according to the acute toxicity of chemical substances, and belongs to the actual non-toxic grade.
The experimental results are as follows:
item Number of animals Number of deaths Mortality (%)
Example 1 10 0 0
Example 2 10 0 0
Example 3 10 0 0
Example 4 10 0 0
Example 5 10 0 0
The data result shows that the agilawood preparation can be orally taken and has no toxicity.
Experiment example three: acute toxic skin irritation test
Experimental drugs: examples 1-5 the finished spray was prepared.
Experimental animals: 40 rabbits are taken and half of the rabbits are female and male. The finished spray prepared in each example is divided into 5 groups by weight, each group is half male and female, and the skin conditions of the finished spray are observed at different times. Inflammatory reactions such as erythema and edema do not occur on the skin of all rabbits, and the acute skin irritation index is 0.
The experimental results are as follows:
Figure BDA0002934453460000121
the above results show that the eaglewood preparation does not have any irritation to the skin.
The invention provides an agilawood preparation, which is prepared by selecting an agilawood extract as a main raw material component and adding a solubilizer, a cosolvent and an air regulating agent in a reasonable compatibility mode, so that the precipitation and the more sufficient mutual fusion of effective components in agilawood are further promoted, and the air regulating agent can promote the smooth breathing of a user. The sweetening agent and the flavoring agent add faint scent to the preparation. The preparation method of the agilawood preparation has simple flow, wide and rich use sources of raw materials, and the prepared product has safety and stability, has no toxic or side effect, and is suitable for mass production. The final product can be widely applied in spray, aroma pill, and incense product.
While particular embodiments of the present invention have been illustrated and described, it will be appreciated that the present invention is not limited to the above-described alternative embodiments, and that various other forms of product may be devised by anyone in light of the present invention. The foregoing detailed description should not be construed as limiting the scope of the invention, and it will be understood by those skilled in the art that modifications may be made to the technical solutions described in the foregoing embodiments, or that equivalent substitutions may be made to some or all of the technical features thereof, without departing from the spirit and scope of the invention, and that these modifications or substitutions may not substantially depart from the essence of the corresponding technical solutions.

Claims (10)

1. The agilawood preparation is characterized by being prepared from the following raw materials in parts by mass:
20-150 parts of agilawood extract, 8-60 parts of solubilizer, 5-50 parts of cosolvent, 2-5 parts of air regulator, 2-7 parts of sweetener and 2-7 parts of aromatizer.
2. The agilawood preparation according to claim 1, wherein the preparation is mainly prepared from the following raw materials in parts by mass:
50-120 parts of agilawood extract, 20-48 parts of solubilizer, 10-38 parts of cosolvent, 2.5-4.5 parts of air regulator, 3-5 parts of sweetener and 3-5 parts of aromatizer.
3. The agilawood preparation according to claim 2, wherein the preparation is mainly prepared from the following raw materials in parts by mass:
80 parts of agilawood extract, 32 parts of solubilizer, 30 parts of cosolvent, 3.5 parts of air regulator, 4 parts of sweetener and 4 parts of excipient.
4. The formulation according to any one of claims 1 to 3, wherein the solubilizer comprises hydrogenated castor oil;
the hydrogenated castor oil comprises one or more of PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil and PEG-80 hydrogenated castor oil;
the co-solvent comprises glycerol.
5. The formulation according to any one of claims 1 to 3, wherein said gas modifier comprises menthone glycerol ketal;
the sweetener comprises trichlorogalactose.
6. The formulation according to any one of claims 1 to 3, wherein the said perfuming agent comprises one or more of menthol and bromelain.
7. The preparation method of the agilawood preparation according to any one of claims 1 to 3, wherein the preparation method comprises the steps of selecting the agilawood extract, the solubilizer, the cosolvent, the air regulator, the sweetener and the aromatizer according to corresponding proportions, uniformly mixing, adding the preservative and the solvent, uniformly mixing, filtering, and sterilizing to obtain a finished product.
8. The method for preparing an agilawood formulation according to claim 7, wherein the preservative comprises lysozyme and sodium benzoate;
the mass ratio of the lysozyme to the sodium benzoate is 1-3: 1-2;
the solvent water;
the mass ratio of the total mass of the agilawood extract, the solubilizer, the cosolvent, the air regulator, the sweetening agent and the flavoring agent to the mass of the preservative to the mass of the solvent is 10-20: 2-4: 3-5.
9. The method for preparing agilawood preparation according to claim 7, wherein the sterilization temperature is 80-100 ℃;
the sterilization time is 5-10 minutes.
10. The application of the agilawood preparation is characterized in that the finished agilawood preparation product of any one of claims 1-3 is applied to spray, aromatherapy pills and incense products.
CN202110157791.9A 2021-02-04 2021-02-04 Agilawood preparation and preparation method and application thereof Pending CN112915137A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110157791.9A CN112915137A (en) 2021-02-04 2021-02-04 Agilawood preparation and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110157791.9A CN112915137A (en) 2021-02-04 2021-02-04 Agilawood preparation and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN112915137A true CN112915137A (en) 2021-06-08

Family

ID=76170574

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110157791.9A Pending CN112915137A (en) 2021-02-04 2021-02-04 Agilawood preparation and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN112915137A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113332203A (en) * 2021-06-30 2021-09-03 海南林鹏茶业有限公司 Agilawood skin care product and preparation method thereof
CN115025014A (en) * 2022-05-25 2022-09-09 中国科学院昆明植物研究所 Aquilaria sinensis extract with collagen secretion promoting and antioxidant activities and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1932645A1 (en) * 1968-06-28 1970-01-08 Clin Byla Ets Antiseptic detergent and process for its preparation
CN108272862A (en) * 2018-03-07 2018-07-13 济川药业集团有限公司 A kind of Pudilan oral spray and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1932645A1 (en) * 1968-06-28 1970-01-08 Clin Byla Ets Antiseptic detergent and process for its preparation
CN108272862A (en) * 2018-03-07 2018-07-13 济川药业集团有限公司 A kind of Pudilan oral spray and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
廖建良 等: "沉香提取物的抑菌活性", 《江苏农业科学》 *
张光杰 等: "《药用辅料应用技术》", 31 December 1991, 中国医药科技出版社 *
迟玉杰: "《蛋白质加工技术》", 28 February 2018, 中国轻工业出版社 *
郝利平等: "《食品添加剂》", 31 August 2002, 中国农业大学出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113332203A (en) * 2021-06-30 2021-09-03 海南林鹏茶业有限公司 Agilawood skin care product and preparation method thereof
CN115025014A (en) * 2022-05-25 2022-09-09 中国科学院昆明植物研究所 Aquilaria sinensis extract with collagen secretion promoting and antioxidant activities and application
CN115025014B (en) * 2022-05-25 2023-03-14 中国科学院昆明植物研究所 Aquilaria sinensis flower extract with collagen secretion promoting and antioxidant activities and application

Similar Documents

Publication Publication Date Title
CN108158869B (en) Antibacterial wet tissue liquid, wet tissue and preparation method of wet tissue
CN104224633B (en) A kind of pure tree peony heal-care essential oil and preparation method thereof
CN103432047B (en) Natural preservative composition and application thereof in cosmetics
KR101068151B1 (en) Composition comprising of plant extract having antimicrobial and antiseptic activity and the use thereof
JP6626902B2 (en) Antimicrobial herbal composition, method for producing and using the same
CN104738033A (en) Preservative composition derived from plants
CN102429848B (en) Dextroborneol perfume
CN112915137A (en) Agilawood preparation and preparation method and application thereof
CN107822945A (en) One kind is matched unartificial yeast composition, preparation method and applied in cosmetics
CN106619380A (en) Anti-acne essence
CN111759885A (en) Sophora flavescens composition, sophora flavescens gel and preparation method thereof
CN109329319B (en) Preparation method of traditional Chinese medicine fermented mosquito repellent liquid, stock solution and diluent thereof
CN101461385B (en) Bacteriostat of gram positive bacteria and gram negative bacteria and use thereof
CN104585244A (en) Method for preparing radix fici simplicissimae extract, radix fici simplicissimae extract and application of extract
CN101461558B (en) Aspergillus bacteriostatic agent and use thereof
CN109350570B (en) Cosmetic preservative based on natural plant components and application thereof
KR20220105712A (en) Manufacturing method of antimicrobial composition comprising extract of herbal mixture and antimicrobial composition thereof
CN107822962A (en) The Anti-bacterium hand cream that a kind of baby is applicable
CN105193686B (en) A kind of Feminine care solution and preparation method thereof
CN108815546B (en) Lemon-flavored natural plant freshener with insect expelling and antibacterial functions
CN103637920A (en) Repellent floral water for children for eliminating heat rash and relieving itching
CN110402969A (en) A kind of environmental type plant source thimerosal
KR101898060B1 (en) Natural aroma essential oil water soluble composition for humidifier disinfectant and the method of manufaturing the same
CN114848553A (en) Natural preservative and application thereof
CN104745302A (en) Preparation method of natural jasmine flower water

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210608